Month: December 2019

TLC Announces Development and License Agreement with Birdie Biopharmaceuticals for NanoX™ Immunotherapy Product
  • December 9, 2019
  • admin

SOUTH SAN FRANCISCO, CA and TAIPEI, Taiwan – December 9, 2019 – Taiwan Liposome Company, Ltd. (“TLC”) (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in osteoarthritis, pain management, ophthalmology and oncology, today announced the signing of […]

Read More
Seven and Eight BioPharmaceuticals, Inc. Announces Clinical Collaboration to Evaluate BDB001 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
  • wpengine

EDISON, N.J.–(BUSINESS WIRE)–Seven and Eight BioPharmaceuticals Inc. announced today that it has signed a clinical research collaboration agreement with Merck (known as MSD outside the US and Canada), through a subsidiary, to explore the combination of Seven and Eight’s BDB001, an immune modulator targeting toll-like receptors (TLR) 7 and 8, and Merck’s anti-PD-1 therapy, KEYTRUDA® […]

Read More